These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20740678)

  • 21. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential conflict between TRIPS and GATT concerning parallel importation of drugs and possible solution to prevent undesirable market segmentation.
    Lo CF
    Food Drug Law J; 2011; 66(1):73-83, ii. PubMed ID: 24505847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proposed EU-India free trade agreement could impede manufacture of generic HIV drugs.
    Chu SK
    HIV AIDS Policy Law Rev; 2011 Apr; 15(2):22-3. PubMed ID: 21688702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
    Ooms G; Forman L; Williams OD; Hill PS
    BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ethics of intellectual property rights in an era of globalization.
    Shah AK; Warsh J; Kesselheim AS
    J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Why are generic drugs being held up in transit? Intellectual property rights, international trade, and the right to health in Brazil and beyond.
    Rosina MS; Shaver L
    J Law Med Ethics; 2012; 40(2):197-205. PubMed ID: 22789040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 28478430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
    Jain D; Darrow JJ
    Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canada and access to medicines in developing countries: intellectual property rights first.
    Lexchin J
    Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
    Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
    Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Learning from practice: compulsory licensing cases and access to medicines.
    Stirner B; Thangaraj H
    Pharm Pat Anal; 2013 Mar; 2(2):195-213. PubMed ID: 24237026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.
    Satyanarayana K; Srivastava S
    Open AIDS J; 2010 Jan; 4():41-53. PubMed ID: 20148091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
    Townsend B; Gleeson D; Lopert R
    Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
    Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
    AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
    [No Abstract]   [Full Text] [Related]  

  • 38. Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health.
    Beck EJ; Passarelli C; Lui I; Guichard AC; Simao M; De Lay P; Loures L
    Antivir Ther; 2014; 19 Suppl 3():117-23. PubMed ID: 25310477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Learning from practice: compulsory licensing cases and access to medicines.
    Stirner B
    Pharm Pat Anal; 2012 Nov; 1(5):555-75. PubMed ID: 24236925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 10 years after implementation of TRIPS obligations in India.
    Pawar MD
    Pharm Pat Anal; 2015; 4(3):147-59. PubMed ID: 26030078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.